|
1
|
Yang JD and Roberts LR: Epidemiology and
management of hepatocellular carcinoma. Infect Dis Clin North Am.
24:899–919. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duan XY, Zhang L, Fan JG and Qiao L: NAFLD
leads to liver cancer: Do we have sufficient evidence? Cancer Lett.
345:230–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karagozian R, Derdák Z and Baffy G:
Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism.
63:607–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakagawa H, Umemura A, Taniguchi K,
Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E,
Hidalgo J, et al: ER stress cooperates with hypernutrition to
trigger TNF-dependent spontaneous HCC development. Cancer Cell.
26:331–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han XJ, Dong BW, Liang P, Yu XL and Yu DJ:
Local cellular immune response induced by ultrasound-guided tumor
bed superantigen injection after percutaneous microwave coagulation
therapy for liver cancer. Zhonghua Zhong Liu Za Zhi. 31:602–606.
2009.(In Chinese). PubMed/NCBI
|
|
7
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holcik M, Gibson H and Korneluk RG: XIAP:
Apoptotic brake and promising therapeutic target. Apoptosis.
6:253–261. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liston P, Fong WG and Korneluk RG: The
inhibitors of apoptosis: There is more to life than Bcl2. Oncogene.
22:8568–8580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maniwa Y, Yoshimura M, Obayashi C, Inaba
M, Kiyooka K, Kanki M and Okita Y: Association of p53 gene mutation
and telomerase activity in resectable non-small cell lung cancer.
Chest. 120:589–594. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Graziano SL, Tatum A, Herndon JE II, Box
J, Memoli V, Green MR and Kern JA: Use of neuroendocrine markers,
p53 and HER2 to predict response to chemotherapy in patients with
stage III non-small cell lung cancer: A cancer and leukemia group B
study. Lung Cancer. 33:115–123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Green DR and Kroemer G: Cytoplasmic
functions of the tumour suppressor p53. Nature. 458:1127–1130.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song LP, Li YP, Wang N, Li WW, Ren J, Qiu
SD, Wang QY and Yang GX: NT4(Si)-p53(N15)-antennapedia induces cell
death in a human hepatocellular carcinoma cell line. World J
Gastroenterol. 15:5813–5820. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C
and Wei Y: Proapoptotic protein Smac mediates apoptosis in
cisplatin-resistant ovarian cancer cells when treated with the
antitumor agent AT101. J Biol Chem. 287:68–80. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed
SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, et al:
Prognostic significance of XIAP expression in DLBCL and effect of
its inhibition on AKT signalling. J Pathol. 222:180–190. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shangary S and Wang S: Targeting the
MDM2-p53 interaction for cancer therapy. Clin Cancer Res.
14:5318–5324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shangary S, Qin D, McEachern D, Liu M,
Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, et
al: Temporal activation of p53 by a specific MDM2 inhibitor is
selectively toxic to tumors and leads to complete tumor growth
inhibition. Proc Natl Acad Sci USA. 105:3933–3938. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scoumanne A and Chen X: Protein
methylation: A new mechanism of p53 tumor suppressor regulation.
Histol Histopathol. 23:1143–1149. 2008.PubMed/NCBI
|
|
19
|
Lu C and El-Deiry WS: Targeting p53 for
enhanced radio- and chemo-sensitivity. Apoptosis. 14:597–606. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hall PA, Ray A, Lemoine NR, Midgley CA,
Krausz T and Lane DP: p53 immunostaining as a marker of malignant
disease in diagnostic cytopathology. Lancet. 338:5131991.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martinazzi M, Crivelli F, Zampatti C and
Martinazzi S: Relationship between p53 expression and other
prognostic factors in human breast carcinoma. An
immunohistochemical study. Am J Clin Pathol. 100:213–217. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen W, Li J, Liu C, Chen X, Zhu Y, Yang
Y, Gong Y, Wang T, Miao X and Nie X: A functional p53 responsive
polymorphism in KITLG, rs4590952, does not affect the risk of
breast cancer. Sci Rep. 4:63712014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ramp U, Krieg T, Caliskan E, Mahotka C,
Ebert T, Willers R, Gabbert HE and Gerharz CD: XIAP expression is
an independent prognostic marker in clear-cell renal carcinomas.
Hum Pathol. 35:1022–1028. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong Y, Zhong R and Hang Z: The
association study and its clinical significance of the expression
of P53, AR and ER in the primary hepatocelluar carcinoma (liver
cancer) and surrounding tissue. Int Med Health Guid News. 12:12–14.
2006.
|
